Introduction
Primary effusion lymphoma (PEL) is an unusual and aggressive lymphoproliferative disease associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) (Chang et al., 1994; Cesarman et al., 1995) . PEL occurs predominantly in immunocompromised individuals such as AIDS patients (Drexler et al., 1998) . The disease has been characterized as being of Bcell origin and although the exact maturation stage of PEL cells is still controversial (Matolcsy et al., 1998; Carbone et al., 2000b) , it is thought to arise from cells of a mature, postgerminal center, preterminal differentiation stage (Nador et al., 1996; Gaidano et al., 1997) . PEL cells lack expression of most typical B-cell surface markers such as CD20, CD22, and CD19, as well as expression of surface immunoglobulin (Ig) (Drexler et al., 1998) . In fact, identification of PEL cells as being of B-cell origin was ultimately based on genotypic analysis demonstrating Ig gene rearrangement in all PEL cases.
B-cell-specific expression of immunoglobulin genes is regulated by the complex interaction between regulatory DNA elements and B-cell-specific transcription factors (reviewed in Singh, 1994; Reya and Grosschedl, 1998) . Among the regulatory DNA elements, the l2-4 and kE3 0 light-chain enhancers contain a composite Ets/IRF element that is essential for their activity (Pongubala et al., 1992; Eisenbeis et al., 1993 Eisenbeis et al., , 1995 . This site is coordinately regulated by the transcription factors PU.1 and IRF-4, which form a ternary complex and synergistically activate transcription (Brass et al., 1996 (Brass et al., , 1999 . Such a composite Ets-IRF element is present as well in the CD20 promoter, among others (Himmelmann et al., 1997) . Interferon regulatory factor (IRF)-4 is a member of the IRF family of transcription factors that regulate cytokine expression, cell growth, and immunomodulation (reviewed in Marecki and Fenton, 2002; Mamane et al., 2002b; Pernis, 2002) . IRF-4 expression is specifically restricted to the lymphoid and myeloid compartments (Eisenbeis et al., 1995) , and in B cells expression is associated with the final steps of intragerminal center B-cell differentiation and maturation towards plasma cells (Falini et al., 2000) . At the molecular level, IRF-4 has a weak intrinsic DNA binding activity and its transactivation potential with respect to the Ets-IRF element depends on the formation of a complex with PU.1 (Pongubala et al., 1992; Eisenbeis et al., 1993 Eisenbeis et al., , 1995 Brass et al., 1996) .
PU.1 is a member of the Ets family of transcription factors that plays an essential role in the development of B cell and myeloid lineages (Scott et al., 1994; DeKoter and Singh, 2000) . In B cells, PU.1 is expressed at all stages of maturation (excluding plasma cells) and it regulates B-cell-specific genes including the m heavy chain (Nelsen et al., 1993; Rao et al., 1997) , the Ig light chains (l and k) (Pongubala et al., 1992; Eisenbeis et al., 1993) , Iga (Feldhaus et al., 1992) , Igb (Omori and Wall, 1993 ), Bruton's Tyrosine kinase (Btk) (Muller et al., 1996) , and the Ig J chain (Shin and Koshland, 1993) . Expression of PU.1 is regulated at the transcriptional level by the dual action of an Ets binding site and an octamer motif (5 0 -ATGCAAAT-3 0 ) (Chen et al., 1996) . The Ets site binds PU.1, thus leading to an autoregulatory stimulatory loop. The octamer site can be bound by either Oct-1 or Oct-2 transcription factors, with Oct-2 exhibiting a higher transactivation potential than Oct-1 (Chen et al., 1996) .
Oct-1 and Oct-2 possess different patterns of expression in vivo: whereas Oct-1 is ubiquitously expressed, Oct-2 is mainly restricted to the B lymphoid compartment, and it is involved in B-cell-specific gene expression. The transactivation potential of Oct-1 and Oct-2 is greatly enhanced by interactions with the B-cell-specific coactivator BOB-1/OcaB (Gstaiger et al., 1995; Strubin et al., 1995) . Although knockout studies have failed to show an essential role for either Oct-2 (Corcoran et al., 1993) or BOB-1/OcaB (Schubart et al., 2001) in immunoglobulin gene expression, the Oct-2
, or double knockout mice showed defects in events that occur after B-cell activation such as germinal center formation and maintenance of the peripheral B-cell pool. Moreover, studies of somatic cell hybrids demonstrated that B-cell-specific genes were coordinately silenced in mature B cells when fused to a non-B-cell line (Lieberman et al., 1993) . The extinction phenomenon was correlated with loss of Oct-2 expression and could be reversed by ectopic expression of Oct-2 (Radomska et al., 1994; Sharif et al., 2001) . Both knockout mice and somatic cell hybrid studies thus ascribe an essential role to Oct-2 in late-stage B-cell development.
In the present study, we sought to examine the expression profile of B-cell-specific transcription factors in HHV-8-induced primary effusion lymphoma cells. Our results indicate that in B-cell lines derived from PEL, transformation is associated with an overexpression of IRF-4, as well as with the loss of expression of PU.1,Oct-2, IRF-8/ICSBP, and BSAP/Pax5. These dramatic alterations in B-cell-specific transcription factors may thus contribute to lymphomagenesis and to the development of the non-B, non-T phenotype in PEL cells.
Results

Constitutive expression of IRF-4 in PEL is concomitant with a downregulation of PU.1
The transcription factor IRF-4 requires physical association with PU.1 in order to efficiently bind and transactivate target Ets-IRF sequences found in the light-chain gene enhancers (Eisenbeis et al., 1995) . Analysis of IRF-4 protein levels by immunoblot demonstrated constitutive IRF-4 levels in all PEL cell lines examined (BCBL-1, BC-3, and BCP-1), compared to the control Burkitt's lymphoma BJAB cells, which showed no significant level of expression ( Figure 1a ). In contrast, no PU.1 protein could be detected in any of the PEL cell lines (Figure 1b) . Surprisingly, the expression pattern of IRF-8, the IRF family member most closely related to IRF-4, was inversely related to IRF-4; that is, IRF-8 was expressed in BJAB, but not in PEL cells (Figure 1c ). The levels of Spi-B, another Ets family member that binds similar DNA elements and activates many of the same target genes as PU.1, remained constant in two of the three PEL cell lines compared to BJAB (Figure 1d ).
To determine if the overexpression of IRF-4, together with the abrogation of PU.1 expression in PEL cells disrupted the regulation of B-cell-specific genes, electrophoretic mobility shift assay (EMSA) analysis was performed using the composite Ets-IRF element found in the lB and kE3 0 light-chain promoters (Figure 2 ). In control BJAB cells, a protein-DNA complex was easily observed using the lB or the kE3 0 probe ( (Brass et al., 1996 (Brass et al., , 1999 .
The B-cell-specific transcription factor Oct-2 is not expressed in PEL cells
In B cells, the PU.1 promoter is regulated mainly through an octamer motif located at position À57 to À51 upstream of the PU.1 mRNA start site (Chen et al., 1996) . The octamer site can be occupied by either member of the octamer binding factor (Oct) family: the ubiquitous Oct-1 or the B-cell-specific factor Oct-2, with the latter displaying the highest transactivation capacity in B cells (Chen et al., 1996) . To examine the status of Oct-1 and Oct-2 binding and its role in transcriptional activation, EMSA analysis was performed with an octamer sequence (Figure 3a) . A dramatic reduction in Immunoblot analysis revealed that Oct-2 protein expression was completely absent in all three PEL cell lines (Figure 3b ). Since the transactivation potential of the octamer binding factors is enhanced by binding of the coactivator BOB-1/OcaB (Chen et al., 1996) , the expression of the cofactor was also examined. Protein expression of the coactivator BOB-1/Oca-B was downregulated in PEL cells to different extents depending on the cell line ( Figure 3c) ; BOB-1/Oca-B was highly expressed in BJAB ( Figure 3c , lane 1), whereas BOB-1/OcaB levels were about four fold lower in BCBL-1 cells compared to control BJAB ( Figure 3c , lane 2); in BC-3 and BCP-1 expression of BOB-1/OcaB was either completely absent or below detection limits (Figure 3c , lanes 3 and 4).
Ectopic expression of Oct-2 restores the activity of the PU.1 promoter in PEL cells
To examine the functional role of Oct-2 expression on the PU.1 promoter, a luciferase assay was performed with the full-length PU.1 promoter, as well as truncated promoters lacking the Oct and Ets sites (Figure 4) . In control BJAB cells, PU.1 promoter activity was approximately 200-fold higher than the activity of the truncated PU.1 +34 promoter (Figure 4 , compare lanes 1 and 4). The importance of the octamer site in regulating PU.1 expression in B cells was substantiated by the low activity of the mPU-39 construct, which contains the promoter proximal PU.1 binding site, but lacks the octamer motif ( Figure 4, lane 2) . The 5 0 distal region (from -334 to -86), however, does not contain important regulatory sites for promoter activity, since the mPU-86 construct has equivalent transactivation potential as the full-length promoter in BJAB cells (Figure 4, compare lanes 3 and 4) . In contrast, in BCBL-1 cells, only a basal level of PU.1 promoter activity was observed with the full-length promoter (Figure 4 , compare lanes 1 and 5). Significantly, coexpression of increasing amounts of an Oct-2 expression plasmid in PEL cells resulted in a dose-dependent increase in promoter activity, comparable to that observed in BJAB cells (Figure 4 , lanes 6-8). Thus, the absence of PU.1 protein in PEL cells appears to be directly related to the transcriptional block imposed by the complete lack of Oct-2 expression.
The activity of a composite Ets-IRF site is restored by ectopic PU.1 expression Activity of the lB and kE3 0 enhancer elements requires the synergistic activity of PU.1 and IRF-4 on the composite Ets-IRF site found in both enhancers. To test the activity of the lB site in PEL cells, the construct B4-TKCAT, which contains four copies of the Ets-IRF site found in the lB enhancer element, was transfected into control BJAB or PEL BCBL-1 cells. In control BJAB cells, B4-TKCAT displayed a sixfold increase in promoter activity compared to the empty vector TK-CAT (Figure 5a , columns 1 and 2). However, in BCBL-1 cells, the activity of the composite lB construct was approximately equivalent to that of the empty vector (Figure 5a , columns 4 and 5). However, increasing amounts of PU.1 transfected together with B4-TKCAT restored the activity of the lB-driven construct to levels comparable to those observed in BJAB cells (Figure 5b , columns 2-6), thus indicating that functional activity of the Ets-IRF sites in PEL cells could be restored by PU.1 expression.
Oct-2 and PU.1 expression in other mature-B-cell lymphomas
Recent studies have indicated that disruption of B-cellspecific transcription factor activity may also occur in other forms of B-cell lymphoma, particularly in classical Hodgkin's disease (reviewed in Chan, 2001; Dolcetti et al., 2001) . To directly compare transcription factor levels in PEL with other mature B-cell-derived lymphomas, protein levels were assessed in a panel of cell lines derived from Burkitt's Lymphoma, a disease originating from early germinal center B cells and characterized by c-myc gene rearrangement (reviewed in Hecht and Aster, 2000) , classical Hodgkin's lymphoma, a clonal disease of B-cell origin that arises from late germinal center B Fold Induction Figure 4 The activity of the PU.1 promoter is abrogated in PEL cells, but can be recovered by ectopic expression of Oct-2. The luciferase reporter gene was placed under the control of the fulllength murine PU.1 promoter (mPU-334, black bars) or truncated promoter constructs lacking the distal 5 0 region (mPU-86, dark gray bar), the Oct and Sp1 sites (mPU-39, light gray bar), or the Oct, Sp1 and PU.1 sites (mPU+34, white bar). The schematic representation of the mPU-Luc plasmids includes the location of the Oct site (), the Sp1 site ( ), and the PU.1 site (J). For the transactivation assay, 10 mg of each construct was electroporated into BCBL-1 (lanes 5-8) or BJAB (lanes 1-4) cells. An Oct-2 doseresponse was performed in BCBL-1 cells by cotransfecting increasing amounts of pCGOct-2 expression vector along with the mPU-334 reporter construct (lanes 6-8). Transfection efficiency was determined by cotransfection with 1 mg of pRL-TK renilla reporter gene. Fold induction was calculated by comparing the activity of the full-length promoter (mPU-334) to that of the truncated promoter (mPU+34). Data represent a typical experiment performed in duplicate Disruption of B-cell transcriptional program in PEL cell lines M Arguello et al lymphocytes (reviewed in Chan, 2001) , and primary effusion lymphoma, also of late/post GC origin ( Figure 6 ). Immunoblot analysis demonstrated that PU.1 and Oct-2 expression was consistently found in Burkitt's lymphoma-derived cell lines (BJAB, Namalwa, BL-2, BL-30, and BL-41. Figure 6, lanes 1, 8, 9 , 10, and 11). As previously reported (Re et al., 2001; Torlakovic et al., 2001) , PU.1 and Oct-2 expression was strongly downregulated in the Hodgkin's lymphoma cell lines L-428 ( Figure 6 , lane 6) and KM-H2 (Figure 6, lane 7) , mirroring the results obtained in PEL cell lines ( Figure 6 , lanes 2-5). Additionally, expression of BSAP/Pax-5 and IRF-8/ICSBP was assessed in both PEL and cHD cell lines, since it has been reported that BSAP/Pax-5 expression is downregulated in cHD cells (Hertel et al., 2002) and we have found a downregulation of IRF-8 levels in PEL cells. The levels of both BSAP/Pax5 and ICSBP transcription factors were dramatically decreased and, furthermore, the expression patterns were once again comparable between cHD and PEL. However, the decrease in protein expression was more profound in PEL cell lines. These results demonstrate a pattern of transcription factor silencing that is not exclusive to PEL cells, but rather is shared among certain types of mature B-cell lymphomas.
Discussion
The results of the current study demonstrate that PEL cells have undergone a severe disruption in the expression of B-cell-specific transcription factors, specifically IRF-4, PU.1, Oct-2, BOB-1/OcaB, BSAP/Pax5, and IRF-8/ICSBP. PEL cells are characterized by a constitutive expression of IRF-4, coupled with a striking absence of two important B-cell-specific factors: Oct-2 and PU.1. Oct-2 ablation plays a role in the Disruption of B-cell transcriptional program in PEL cell lines M Arguello et al downregulation of PU.1 expression in PEL cells, which in turn leads to an impaired activity of PU.1 responsive elements such as the Ets-IRF sites found in the lB and kE3 0 immunoglobulin (Ig) light-chain enhancers and the CD20 promoter. Ectopic expression of PU.1 in BCBL-1 cells fully restored the activity of the composite Ets-IRF site, indicating that it is the absence of PU.1 that accounts for the loss of Ig light-chain enhancer activity in PEL cells.
PU.1 expression is controlled in part by an octamer site located in the À57 to À51 region of the PU.1 promoter and composed of the sequence 5 0 -ATG-CAAAC-3 0 . This site is activated preferentially by the lymphoid-specific factor Oct-2, with the activity being further enhanced by interaction with the coactivator BOB-1/Oca-B. Mature, activated B cells express high levels of Oct-2 and BOB-1 (Re et al., 2001) . In PEL cells, however, Oct-2 expression was completely abrogated, although Oct-1 levels were normal. As a consequence of the loss of Oct-2, the activity of a reporter gene under the control of the PU.1 promoter was negligible in BCBL-1 cells. Interestingly, transient expression of Oct-2 reconstituted PU.1 promoter activity to control levels, whereas endogenous Oct-1 was unable to restore PU.1 promoter activity and thus could not functionally replace Oct-2. BCBL-1 is the only PEL cell line that retained BOB-1/OcaB expression, albeit at significantly reduced levels. It is possible that partial expression of the coactivator could explain why recovery of the PU.1 promoter activity was observed when Oct-2 activity was reconstituted in BCBL-1 cells. Our studies thus suggest that it is the loss of the B-cell-specific Oct-2 protein that contributes to the transcriptional shutoff of PU.1. In contrast to the dramatic alterations in IRF-4, Oct-2, and PU.1, expression of the Ets family member Spi-B was generally not altered in PEL cell lines. Although it has been reported that Spi-B is able to bind to the same DNA motifs as PU.1, in our hands endogenous Spi-B was unable to replace PU.1 in the transactivation of the lB element. In recent experiments, IRF-4 was also shown to be constitutively expressed in HTLV-1-infected leukemia T cells (Sharma et al., 2002) . Furthermore, in the T-cell context, IRF-4 was shown to act as a global transcriptional repressor of genes involved in cell cycle regulation, apoptosis, DNA repair and cell adhesion (Mamane et al., 2002a) . In the B-cell context, IRF-4 acts as a strong transcriptional activator of downstream target genes by virtue of its association with PU.1. In the absence of its transcriptional partner, it will be interesting to determine if IRF-4 also acts as a repressor of B-cell-specific transcription in PEL and cHD.
Among the genes downregulated when Oct-2 is absent in PEL cells are PU.1 and BOB-1/OcaB, two factors that are key for B-cell development, maturation, and survival. Once deprived of Oct-2, BOB-1/OcaB, and PU.1 expression, PEL cells may lose the ability to express surface molecules in a silencing-like event, such as previously observed in hybrid B cells (Lieberman et al., 1993; Radomska et al., 1994) . Oct-2 has previously been shown to regulate the expression of an array of B-cell-specific genes, as demonstrated in hybrid B cells, fused either to myeloma or T cells (Junker et al., 1990; Radomska et al., 1994) . Fusion of an Ig-secreting cell (plasmacytoma) to a T-cell lymphoma led to cessation Oct-2 production as well as immunoglobulin, J chain, and other B-cell-specific genes. However, when Oct-2 extinction was prevented through stable transfection of an Oct-2 expression plasmid, all B-cell-specific genes escaped silencing, including the endogenous Oct-2. Interestingly, endogenous or exogenous Oct-1 could not rescue the cells from B-cell-specific gene silencing (Radomska et al., 1994; Sharif et al., 2001) , a result that is consistent with the present study. We are currently investigating the role of PU.1 and Oct-2 abrogation in the expression of other B-cell molecules such as the m and d heavy chains, the J chain, and CD20, in the hope of elucidating the role of these two factors in the 'incomplete' phenotype observed in PEL cells.
The results of this study together with other recent experimentation (Re et al., 2001; Stein et al., 2001; Torlakovic et al., 2001; Hertel et al., 2002 ) provide a preliminary model describing B-cell transcription factor ablation in mature B-cell lymphomas, and is represented schematically in Figure 7 ; in normal mature B cells, expression of surface antigens is regulated both by extracellular signals and by developmentally regulated transcription factors. These transcription factors act coordinately to direct the expression of B-cell surface antigens, and in particular, B-cell receptor (BCR) components (Figure 7a) . In PEL cells, however, abrogation of the expression of essential B-cell transcription factors such as BSAP/Pax5, Oct-2, and BOB-1/ OcaB by as yet uncharacterized mechanisms, leads to silencing of the expression of downstream factors (for example PU.1, a gene under the transcriptional control of Oct-2 and BOB-1/OcaB) in a cascade-like event. The ablation of Oct-2, BSAP/Pax5, BOB-1/OcaB, PU.1, and IRF-8 expression is a potential cause of the lack of BCR as well as other B-cell surface markers observed in PEL cells (Figure 7b) .
A limited survey of the expression patterns of Oct-2, PU.1, IRF-4, IRF-8, and BSAP/Pax5 in PEL and other mature B-cell-derived lymphomas demonstrated that classical Hodgkin's disease (cHD) cells have a transcription factor profile very similar to that of PEL, with increased levels of IRF-4 and reduced or ablated expression of the remaining transcription factors: Oct-2, PU.1, IRF-8, and BSAP/Pax5. In contrast, the profile of all Burkitt's lymphoma cell lines was exactly opposite to that of PEL cells. The direct comparison of two or more cell lines derived from different lymphomas raises the question as to whether the observed changes are specific to the phenotypic characteristics of the disease or if they represent global differences caused by cell-line skewing. To address this question, microarray studies were conducted using a human array containing 1700 genes to compare gene expression between the PEL cell line BCBL-1, the cHD cell line L-428, and Burkitt's lymphoma cell line BJAB (data not shown). Preliminary results indicated that transcription factors Oct-2, PU.1, IRF-4, IRF-8, and BSAP/Pax5 belong to a limited group of genes (o5% of the total 1700 genes examined) whose expression significantly changes in PEL or cHD, compared to the control Burkitt's lymphoma cell line BJAB. It is interesting to note that all three lymphomas have been described as arising from mature B cells: Burkitt's lymphoma originates from early GC lymphocytes, whereas both Hodgkin's and PEL cells are ascribed to a later developmental stage, either late or post-GC ). As such, both cHD and PEL cells are expected to present surface immunoglobulin light and heavy chains as well as surface Iga and Igb -all components of the B-cell receptor complex-but fail to do so.
Interestingly, the absence of Oct-2 and PU.1 has been associated with loss of surface immunoglobulin and surface marker expression in classical Hodgkin's lymphoma (Stein et al., 2001) , a phenotype also observed in PEL. Since Hodgkin's disease may or may not be associated with viral infection (in particular EBV, reviewed by Dolcetti et al., 2001) , such changes in transcription factor profiles may represent a hallmark of lymphoma development rather than a particular consequence of HHV-8 infection in PEL. However, it remains to be determined whether specific viral functions encoded by HHV-8, or other transformationrelated events lead to the downregulation of Oct-2 expression and the 'null' phenotype of PEL cells. This study represents the first demonstration that elevated constitutive IRF-4 production is coupled with abrogation of Oct-2, PU.1, BSAP/Pax5, and IRF-8 expression in PEL cells, and provides insight into the molecular transcriptional changes that occur in Primary Effusion Lymphoma. Altogether, this work and other recent studies suggest that transcription factor ablation may be a common theme in the development of certain subtypes of late-stage B-cell lymphoma.
Materials and methods
Cell lines
BCBL-1, a primary effusion lymphoma cell line infected with HHV-8 but negative for EBV or HIV-1, and BJAB, an EBVnegative Burkitt's lymphoma cell line, were a kind gift from Dr Jae U Jung (Harvard Medical School, MA, USA). Both cell lines were cultured in RPMI 1640 (Wisent) supplemented with 10% FBS, 10 À5 m b-mercaptoethanol, and 8 mg/ml gentamicin. BC-3 (ATCC no. CRL-2277) is a primary effusion lymphoma cell line infected with HHV-8, but negative for both HIV and EBV. BCP-1 (ATCC product number CRL-2294) is an HHV-8 positive, HIV and EBV negative, clonal lymphoma cell line isolated from peripheral blood. Both PEL cell lines were maintained in RPMI 1640 supplemented with 20% FBS and 8 mg/ml gentamicin. CRO-AP6 is an HIV-positive, EBVnegative PEL cell line established from the pleural effusion of a 26-year-old, HIV + patient (described in Carbone et al., 2000a, a kind gift from Dr A Carbone, Centro di Referimento Oncologico, IRCCS, Italy). KM-H2 and L-428 are two wellcharacterized Hodgkin's lymphoma cell lines of B-cell origin (described in Drexler, 1993; Hertel et al., 2002) , BL-2, BL-30, and BL-41 are Burkitt's lymphoma cell lines previously described (Ehlin-Henriksson et al., 1987) , all a kind gift from Dr Sigrun Smola. Namalwa cells are an EBV-positive Burkitt's lymphoma cell line obtained from the ATCC (product number CRL-1432). They were cultured in RPMI 1640 with 10% FBS and 1% sodium pyruvate.
Plasmid constructions
The B4-TKCAT reporter construct was a kind gift from Dr H Singh (University of Chicago, Eisenbeis et al, 1993) . B4-TKCAT contains four copies of the immunoglobulin lB site subcloned upstream of the HSV thymidine kinase promoter in the TK-CAT vector. The PU.1 expression vector PU.1/pECE was a kind gift from Dr M Fenton. The PU.1 cDNA is placed under the transcriptional control of the SV40 early promoter. The luciferase reporters under the control of the murine full-length PU.1 promoter (mPU-334) and deletions (mPU-86, mPU-39, and mPU+34) as well as the Oct-2 and Oct-1 expression vectors (pCGOct-1 and pCGOct-2) were a kind gift from Dr D Tenen (Harvard University) and are described in Chen et al. (1996) .
Whole-cell extract preparation and immunoblot analysis
Whole-cell extracts (WCE) and immunoblot analysis were performed using standard protocols as described (Servant et al., 2001) . Briefly, WCE (50-100 mg) prepared using Nonidet P-40 lysis buffer were subjected to electrophoresis on 10-12% SDS-PAGE gels. Proteins transferred to Trans-Blot s nitrocellulose membrane (Bio-Rad Laboratories) were blocked in PBS containing 5% nonfat dry milk and 0.05% Tween 20 then incubated with 1 mg/ml primary antibody dilutions. After washes, the blots were incubated with a secondary antibody coupled to HRP. Blots were visualized using the ECL detection system from NEN Life Science Products. The following antibodies were used in this study: Anti-IRF-4 goat polyclonal antibody, anti-ICSBP goat polyclonal antibody, anti-PU.1 rabbit polyclonal antibody, anti-Oct-2 rabbit polyclonal antibody, anti-Bob-1 rabbit polyclonal antibody, antiSpi-B goat polyclonal antibody, anti-Pax5 goat polyclonal antibody, all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-b-actin mouse monoclonal antibody was purchased from Sigma and used at a 1 : 10 000 dilution.
Transient transfections and reporter assays
Electroporation was performed at 950 mF and 250 V for both BJAB and BCBL-1 cells. Luciferase assays were performed following a transient transfection of 10 mg of the reporter gene (mPU-334, mPU-86, mPU-39, or mPU+34) and 1.0 mg of the renilla internal control (pRL-TK) into 10 Â 10 6 cells. The doseresponse for Oct-2 was performed in a similar manner, but cotransfecting 0, 1, 2, or 4 mg of the pCGOct-2 expression vector (in which the octamer factor cDNA is under the control of a CMV promoter). The luciferase assay was performed 48 h after transfection using the Promega Dual Luciferase Reporter Assay System. Transfection efficiency was normalized using the renilla activity counts.
CAT assays were performed after transient transfection of 10 mg of the reporter constructs B4-TKCAT, TK-CAT, or pEGFP-C1 into 10 Â 10 6 cells. PU.1 dose-response was performed by cotransfecting 0, 10, 50, 150, or 300 ng of the PU.1/pECE expression vector. The CAT assay was performed 48 h after transfection as follows: cell pellet was resuspended in 0.25 m Tris pH 7.8 and lysed by three rounds of freeze-thaw. Equal volumes of protein extract (50 ml) were placed in a 7 ml glass scintillation vial and heated at 601C for 10 min to deactivate deacetylases, then cooled on ice. To the extracts were added 1 mm chloroamphenicol (Sigma) and 0.4 nCi of 3 Hacetyl-coenzyme A (200.00 mCi/mmol, Perkin Elmer Life Sciences) in a total volume of 250 ml buffered with 100 mm Tris pH 7.8. The mixture was overlaid with Beta Max water immiscible scintillation fluid (ICN Radiochemicals) and incubated at 371C for 6 h. The samples were then analysed in a scintillation counter for 3 H measurement. Transfection efficiency was normalized by %GFP and microgram of protein.
Electrophoretic mobility shift assay (EMSA)
BJAB, BCBL-1, BC-3, and BCP-1 nuclear extracts were prepared as described elsewhere (Osborn et al., 1989) . EMSA analysis using the octamer consensus sequence was performed as described in Chen et al. (1996) . Briefly, 2 Â 10 5 cpm of the [g-32 P]ATP consensus Octamer probe (5 0 -TGT CGA ATG CAA ATC ACT AGA A-3 0 , Sta. Cruz Biotechnology) was incubated with 5-10 mg of nuclear extracts in binding buffer (10 mm HEPES, pH 7.5, 50 mm KCl, 5 mm MgCl 2 , 1 mm EDTA, 1 mm dithiothreitol, 0.1 mg/ml poly(dI/dC), 0.1 mg/ ml BSA, and 5% glycerol) on ice for 30 min. For supershift experiments, 1 ml of anti-Oct-2 antibody (Santa Cruz Biotechnology) or anti-Oct-1 antibody (Sta. Cruz Biotechnology) was added to the reaction. Competition with mutant probe was performed using 1 ml of a mutated octamer probe (5 0 -TGT CGA ATG CAA GCC ACT AGA A-3 0 , Santa Cruz Biotechnology). Supershift with an unrelated antibody was performed by incubation with 1 ml of normal goat serum. Binding reactions were subjected to electrophoresis on a 5% polyacrylamide gel in 0.25 Â TBE at 160 V for 3 h.
Electromobility shift assays using the lB (5 0 -AAA TAA AAG GAA GTG AAA CCA AG-3 0 ) and kE3 0 (5 0 -CCC TTT GAG GAA CTG AAA ACA GA-3 0 ) probes were performed as described above. For supershift experiments, 5 ml of anti-IRF-4 antibody, anti-PU.1 antibody, anti-ICSBP antibody, or anti-Spi-B antibody (Santa Cruz Biotechnology) was added to the reaction.
